 The purpose of this study is to determine whether vaccination with melanoma antigen peptides Melan-AMart-1 both EAA and ELA, NY-ESO-1b analog, Long NY-ESO-1 LP and MAGE-A10 and Montanide, CpG adjuvants and low dose rIL-2 can induce an immune response in melanoma patients and to assess the safety of this vaccination. 